Expert opinion on the introduction of the meningococcal B (4CMenB) vaccine in the EU/EEA
This expert opinion is intended to support national decision-making by summarising the considerations and concerns of some EU/EEA countries when they discussed whether to introduce the 4CMenB vaccine into their national immunisation programmes.
Expert opinion on meningococcal B vaccine – information and suggestions to EU/EEA countries
The ECDC expert opinion provides information on the burden of serogroup B invasive meningococcal disease in the EU/EEA, includes general considerations for 4CMenB introduction such as vaccine immunogenicity, safety, cost-effectiveness, ease of implementation and areas for country collaboration, and highlights different options for vaccine introduction.
Invasive meningococcal disease - Annual Epidemiological Report for 2015
In 2015, 3 121 confirmed cases of invasive meningococcal disease were reported by 30 EU/EEA Member States to ECDC.
Invasive meningococcal disease - Annual Epidemiological Report 2016 [2014 data]
In 2014, 2 760 confirmed cases of invasive meningococcal disease were reported to TESSy. The notification rate was 0.5 cases per 100 000 population, which is lower than in previous years.
Communicable disease threats report, 31 July - 6 August 2016, week 31
This issue of the Communicable Disease Threat Report (CDTR) covers the period 31 July - 6 August 2016 and includes updates on Zika virus, yellow fever in Angola, chikungunya, dengue, West Nile virus and polio.
Systematic review on the incubation and infectiousness/shedding period of communicable diseases in children
Illnesses caused by infectious diseases are common in children in schools or other childcare settings. Currently there is no common EU approach to the control of communicable diseases in schools or other childcare settings, and existing information is uncertain.
External quality assessment scheme for Neisseria meningitidis - 2014
In July 2014, a panel of two viable isolates of N. meningitidis of the major disease-causing serogroups with three simulated cerebrospinal fluid (non-culture) samples for molecular studies, was sent by UK NEQAS to 30 reference laboratories in the IBD-labnet surveillance network for quality assessment testing. This report summarises the diagnostic results submitted by the participating laboratories.